Lung Cancer-Targeting Peptides with Multi-subtype Indication for Combinational Drug Delivery and Molecular Imaging

Chi YH, et al., 7(6):1612-1632, Theranostics, 2017

Histopathologically, lung cancer can be divided into two main types; small-cell lung carcinoma (SCLC) and non-small-cell lung carcinoma (NSCLC). NSCLC is further subdivided into large cell carcinoma (LCC), adenocarcinoma, and squamous cell carcinoma (SCC). Currently, there are no targeted therapies available to treat LCC or SCLC. Described herein is the identification of three new lung cancer-targeting peptides , HSP1, HSP2, and HSP4, which possess diagnostic and therapeutic potential in both SCLC and NSCLC. The binding of HSP peptides (HSP1, HSP2, and HSP4) to H460 LCC cell membrane extract were studied using Bio-Layer Interferometry (BLI). A Pall ForteBio Octet HTX system was used to perform all BLI experiments. Sensorgrams of serial dilutions of HSP peptides binding to membrane components extracted from H460 cells were reported. The association rates (ka), dissociation rates (kd), and dissociation constants (KD) were determined for each binding interaction. Overall findings of this investigation suggest that these newly discovered lung cancer-targeting peptides have the potential to play a key role in the design of targeting therapeutics, molecular imaging, and clinical detection of SCLC and NSCLC.

Read More